Physician profile
Assem Ditch
NPI 1750191763
$799.27
in general payments reported to CMS, 2019-2025
17 companies · $799 in 2025
The $799 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $799.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $99.88 | 2025 | |
| Corium, LLC | $84.75 | 2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $80.99 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $76.55 | 2025 | Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $74.19 | 2025 | Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $47.62 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.57 | 2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $43.83 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $38.80 | 2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $36.67 | 2025 | |
| Tris Pharma INC | $36.51 | 2025 | Dyanavel Xr |
| Alkermes, INC. | $36.35 | 2025 | Aristada, Lybalvi |
| Idorsia Pharmaceuticals US INC | $24.11 | 2025 | Quviviq |
| Biogen, INC. | $23.91 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $19.72 | 2025 | Qelbree |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $15.64 | 2025 | Auvelity |
| Noven Therapeutics, LLC | $14.18 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Assem Ditch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.